Est-ce que IPA pourrait être l’une des deux entreprises de Vancouver? Est-ce qu’il y a un lien avec la nouvelle que le National Research Council of Canada allait les supporter?
Feds to invest $9M in COVID treatments as vaccine rollout ramps up
OTTAWA - Prime Minister Justin Trudeau says the federal government is spending about $9 million toward research into treatments for COVID-19 as authorities work to deploy hundreds of thousands of vaccines in coming weeks.
Trudeau says the investment through the National Research Council of Canada will be used to develop treatments to fight COVID-19 and other viral infections.
He says the funding will go to four Canadian companies working on treatment candidates, including two in Montreal and two in Vancouver.
J’espère presque que ce n’est pas pour IPA! 9 millions divisé en 4… ce n’est pas une énorme marque de confiance!
Today, the National Research Council of Canada (NRC) announced it is providing advisory services and over $9 million in research and development funding through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support 4 therapeutic firms. These include:
Up to $289,032.00 to Bold Therapeutics (Vancouver, BC) for a project to prepare preclinical efficacy data in live SARS-CoV-2 (COVID-19), support preparation for clinical trials, and to support manufacturing of its BOLD-100 investigational therapy to treat patients with viral infections, including COVID-19.
Up to $4,609,000.00 to JN Nova Pharma (Montreal, Que) to assist in the development of a proprietary drug to block coronavirus infection, while reducing the impacts of the disease in patients exhibiting COVID-19 symptoms so they may recover faster.
Up to $4,166,796.00 to Laurent Pharmaceuticals (Montreal, Que) for the clinical development of their LAU-7b antiviral and inflammation controlling therapy for COVID-19 infections.
Up to $109,764.00 to Qu Biologics (Vancouver, BC) for a project to provide proof-of-concept evidence for the safety and efficacy of a preventative treatment as well as therapeutic use of a treatment to protect the lungs and prevent serious COVID-19 infection.
by @newswire on 21 Dec 2020, 08:12
ImmunoPrecise Reports Financial Results and Recent Business Highlights for Second Quarter of 2021 Fiscal Year
- Record Quarterly Revenue of $4,754,545 and Adjusted EBITDA of $795,159
- Announced Strategic Partnership with Mila to Expand AI Capabilities and Functionality of Antibody Development Platform
- Advanced Lead Candidates for COVID-19 PolyTope™ Cocktail Therapy, Preclinical Trials Scheduled to Launch in January 2021
VICTORIA, BC, Dec. 21, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSXV: IPA) (OTCQB: IPATF) today announced financial results for the second quarter of its 2021 fiscal year ended October 31, 2020.
Q2 Fiscal 2021 Financial Highlights:
- Revenue was $4.8 million for the quarter ended October 31, 2020, an increase of $1.6 million, or 50%, compared to $3.2 million in the same quarter last year.
- Adjusted EBITDA was $795,159 for the quarter ended October 31, 2020, an increase of $858,577 compared to ($63,418) in the same quarter last year.
- Current cash balance is $16.8 million as of October 31, 2020 compared to $2.6 million as of the fiscal year end April 30, 2020.
Financial Results
Revenue: The Company’s revenues were $4,754,545 for the three-months ended October 31, 2020 compared to revenues of $3,162,365 for the same period last year, a 50% increase. This was a result of the Company’s increased contract volume, which is due to ongoing emphasis on generating diversified discovery programs utilizing distinctive animal repertoires and multiple technologies with unique advantages.
Research and Development: The Company has invested $1,358,529 in research and has recorded $2,154,577 in grant income and subsidies through October 31, 2020. The Company has been expanding its commitment to research and development initiatives aimed at introducing new services through both internal development as well as through partnerships. The company has also undertaken research and development projects related to COVID-19 and has been awarded government grants and subsidies to support those efforts.
Net Loss. The Company recorded a net loss of $463,583 during the three-months ended October 31, 2020, a decrease of $899,962 from the net loss of $1,363,545 for the three months ended October 31, 2019. The improvement is a result of the Company’s increase in revenue, higher gross profit and grant and subsidy income offset by higher research and development expenses and other operating expenses.
**Non-IFRS Measures. *** Adjusted EBITDA for the three-months ended October 31, 2020 was $795,159, an increase of $858,577 from the Adjusted EBITDA of ($63,418) for the three months ended October 31, 2019. The increase is a result of the increase in revenue, higher gross profit and grant and subsidy income offset by higher research and development expenses and other operating expenses compared to the prior period.
Dr. Jennifer Bath, CEO of ImmunoPrecise, stated, « We have again achieved accelerated revenue growth in the second quarter of Fiscal Year 2021 as we continued to gain market share across different business units. We are anticipating additional commercial opportunities that will bolster our CRO revenues going forward, including within our partnered programs in our subsidiary, Talem Therapeutics. »
Dr. Bath concluded, « The Company’s financial position is strong, providing support for our strategic growth plans in geographical expansion and digital transformations within AI at the intersection of genomics and immunology. We are grateful for the dedication of our employees and partners and remain committed to working with them to enable scientific innovation worldwide. Looking ahead, we will continue to invest in new capabilities that help our partners across the globe progress in their research and bring groundbreaking medicines and treatments to patients in need. »
Recent Business Highlights
-
Selected Lead Formulation for Preclinical PolyTope™ Antibody Cocktail Therapy: In November 2020, ImmunoPrecise announced the nomination the first anti-SARS-CoV-2 cocktail therapy consisting of four, human, synergistic antibodies for preclinical testing. The preclinical trial will examine the safety, tolerability and efficacy of the proposed therapeutic cocktail in the well-defined, SARS-CoV-2, Syrian hamster model.
-
Entered into Technology Partnership with Genmab Targeting Infectious Disease: In November 2020, ImmunoPrecise entered into a research agreement with Genmab A/S, to generate novel bispecific antibody combinations using Genmab’s proprietary DuoBody® platform and IPA’s proprietary antibodies in the field of infectious disease.
-
Announced Strategic AI Partnership with Mila: In November 2020, ImmunoPrecise announced a partnership with Mila, a world-renowned artificial intelligence (AI) research institute, to research and develop novel therapeutics. Through the partnership, the companies will access previously unexplored datasets generated by ImmunoPrecise to explore how to better design new therapeutics against life-threatening disease.
-
Announced Collaboration with Twist Biosciences for the Creation of Novel, Therapeutic Antibody Products: In October 2020, ImmunoPrecise announced a collaboration with Twist Biosciences to leverage Twist’s silicon DNA platform to enhance its antibody therapeutics and expand its early-stage pipeline into a wider range of oncology targets. Following initial discovery work, the companies will then aim to jointly advance the programs through proof-of-concept and preclinical, and eventually clinical, development.
-
Initiated Preclinical Trials for SARS-CoV-2 Vaccines in Collaboration with LiteVax: In September 2020, ImmunoPrecise, in partnership with LiteVax, initiated preclinical trials for a set of vaccine candidates being developed against SARS-CoV-2. The formulations were designed using ImmunoPrecise’s extensive data sources and co-formulated with LiteVax’s novel class of synthetic carbohydrate derivates designed to act as a vaccine adjuvant.
-
Released Second-Generation B Cell Select™: In September 2020, IPA Europe, a subsidiary of ImmunoPrecise, announced the release of a second-generation B-Cell Select platform. The new technology will accelerate antibody identification and discovery capabilities by allowing for increased automation of their selection technology and subsequent single cell cloning.
-
Announced Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks: In September 2020, ImmunoPrecise announced a research collaboration with Zymeworks to utilize their Azymetric™ and EFECT™ platforms for the development of antibody candidates against COVID-19. Candidates obtained from this collaboration will undergo thorough testing using spike proteins provided by the National Research Council Canada and if effective, will proceed to further animal testing.
-
Commenced Application Process to Dual Listing on NASDAQ: In September 2020, ImmunoPrecise announced its application to list on the Capital Market « NASDAQ » exchange. NASDAQ is the world’s pre-eminent exchange for biotech and pharma companies and will expand the Company’s exposure and access to U.S. and international investors.
ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange
VICTORIA, BC, Dec. 23, 2020 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the « Company » or « IPA ») (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeutic antibody discovery and development, is pleased to announce that its common shares have been approved for listing on the NASDAQ Global Market (" Nasdaq « ) under the trading ticker symbol " IPA . » Trading on the Nasdaq is expected to commence at market open on December 30, 2020.
The Company’s Shares will continue to be listed on the TSX Venture Exchange (" TSX-V ") under the symbol " IPA ".
« Our listing on the NASDAQ is a major corporate milestone and reflects the hard work and steadfast dedication of IPA’s global employees and executive team, » stated Dr. Jennifer Bath, CEO of IPA. « We believe the NASDAQ Global Market will enhance long-term shareholder value by improving the Company’s visibility, increasing liquidity, and appealing to institutional investors. »
Jai hate de voir la reaction du titre dans les prochains jours. Intéressant
+20% pas mal
Oui! Potentiel immense
Félicitations à tous et à toutes les investisseurs qui ont navigué la volatilité de 2020 pour profiter des nouveaux sommets aujourd’hui.
Par contre, n’oubliez pas qu’une biotech c’est risqué et qu’il faut aussi se diversifier. Pour la même valorisation, je vous suggère de jeter un coup d’oeil à CLPT qui est actuellement ma plus grosse position personnelle (après QBTC et mes warrants de AKR).
Analyse sympa
21.5$ ATH!!! et joyeux noël!
FINALEMENT! Un bon call! Can’t wait une fois sur le Nasdaq
lol
Lecture en attendant, cible $20. Pour ma part je maintiens une cible de US$1G à moyen terme.
IPA is Making the List - We Checked it Twice and IPA is Coming to
Nasdaq Town!
4a377539-ad36-4719-bb08-88de546f8c1f.pdf (361,6 Ko)
ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program
IMMUNOPRECISE ANTIBODIES LTD. (« Company » or « IPA ») (TSXV: IPA) (Nasdaq: IPA), a leader in full-service, therapeutic antibody discovery and development, today announced joining the COVABELP consortium, comprised of Radboud University Medical Center (Radboudumc) and Eindhoven University of Technology (TU/e). The academic partners of the consortium have been awarded €350,000 from Health Holland under the Eureka Program to develop a SARS-CoV-2-specific therapeutic nanomedicine that is administered via nasal inhalation and that can also be used for in vitro diagnostics.
It is believed that the advantage of this nanomedicine-based therapy is not solely the ability to deliver the therapeutic directly to the lungs of the patient, but also the induction of virus aggregation leading to patient immunity, in effect, simultaneous generation of a vaccination response. In addition, the biochemical properties of the nanoparticles allow for easy adaptation to a format that facilitates the identification of infected individuals by sensitive and rapid virus detection in saliva and nasopharyngeal swabs. The integration of IPA’s expertise in rapidly isolating anti-virus antibody fragments from its in-house antibody libraries, coupled with the robust nanoparticle-based theranostic platform, serves as a proof-of-concept study to enable the rapid detection of future pandemic pulmonary viruses.
The COVABELP program combines IPA’s technologies and expertise in antibody selection, development and engineering of single-domain antibodies (such as VHHs) with Radboudumc’s specialized skills in targeted nanomedicine and TU/e’s thermo-responsive diblock elastin-like peptide (dbELP) technology.
“This is a tremendous opportunity to push the science further as this antibody-based nanomedicine format is hypothesized to have additional therapeutic benefits compared to single monoclonal antibody equivalents,” stated Ilse Roodink, Global Project Lead for the Company’s Coronavirus programs. “Due to the breadth of our antibody discovery capabilities, IPA is very well positioned to deliver anti-virus antibodies in various formats, opening doors for inclusion in different therapeutic and diagnostic approaches. Neutralizing anti-SARS-CoV-2 VHHs, but also scFvs, isolated from our in-house llama and human phage libraries, respectively, are of particular interest for this collaborative program, as they can easily be presented on the nanoparticles.”
IP generated within the COVABELP program will be jointly owned between Radboudumc, TU/e and IPA. IPA will have the first right to protect and commercialize said joint IP. Such commercialization will be subject to a commercial agreement, details of which are to be discussed per occurrence.
About Radboudumc
Radboudumc is one of eight University Medical Centres (UMCs) in The Netherlands. Radboudumc, with nearly 9,000 employees and 3,000 students, is devoted to patient care, education and training, as well as performing excellent basic and clinical research. The Radboudumc aims to have a significant impact on healthcare by providing excellent quality of care and research with a focus on participatory and personalized healthcare. Collaborations with a range of stakeholders such as companies, patient organizations and policy makers are key to achieving that impact. For more information visit www.radboudumc.nl/en/research
About TU/e
Eindhoven University of Technology (TU/e) was founded in 1956 by industry, local government and academia. TU/e is a research-driven university of international standing, where excellent research and education go hand in hand. TU/e focuses on a balanced approach towards education, research and valorization of knowledge in the areas of engineering, science and technology. The TU/e campus is situated in the heart of the high-tech Brainport region in the Netherlands, which is the high-tech growth accelerator of the Dutch economy. With Eindhoven at its center, the region promotes international public-private partnership between academia and industry. As the academic powerhouse of the region, TU/e is equipped with a wide range of high-quality research facilities and equipment. For further information www.tue.nl
Aujourd’hui est le grand jour.
Nasdaq trading et une nouvelle COVID pour jeter de l’huile sur le feu 
Dégringolade… dur à comprendre!